Polymorphisms in hypoxia inducible factor 1 and the initial clinical presentation of coronary disease
Authors:
- Mark A. HlatkyMHMark A. Hlatky
- Thomas QuertermousTQThomas Quertermous
- Derek B. BoothroydDBDerek B. Boothroyd
- James R. PriestJPJames R. Priest
- Alec J. GlassfordAGAlec J. Glassford
- Richard M. MyersRMRichard M. Myers
- Stephen P. FortmannSFStephen P. Fortmann
- Carlos IribarrenCICarlos Iribarren
- Holly K. TaborHTHolly K. Tabor
- Themistocles L. AssimesTAThemistocles L. Assimes
- Robert J. TibshiraniRTRobert J. Tibshirani
- Alan S. GoAGAlan S. Go
- 1 December 2007
- journal article
- Published by Elsevier in American Heart Journal
- Vol. 154 (6) , 1035-1042
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Metabolic Syndrome and Early-Onset Coronary Artery DiseaseJACC, 2006
- Validation of a New Brief Physical Activity Survey among Men and Women Aged 60–69 YearsAmerican Journal of Epidemiology, 2006
- Statin and β-Blocker Therapy and the Initial Presentation of Coronary Heart DiseaseAnnals of Internal Medicine, 2006
- Coronary artery disease and the thrombospondin single nucleotide polymorphismsThe International Journal of Biochemistry & Cell Biology, 2004
- Candidate-gene approaches for studying complex genetic traits: practical considerationsNature Reviews Genetics, 2002
- Vascular-specific growth factors and blood vessel formationNature, 2000
- Development of a hypoxia-responsive vector for tumor-specific gene therapyGene Therapy, 2000
- Hypoxia-Inducible Factor 1Chest, 1998
- HIF‐1α is required for solid tumor formation and embryonic vascularizationThe EMBO Journal, 1998
- Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.Proceedings of the National Academy of Sciences, 1995